Bufalin
Catalog No.: GN10365Purity:>99.50%Synonyms: NSC 89595
Bufalin is a Na+/K+-ATPase inhibitor (α1: Kd = 42.5nM; α2: Kd = 45nM; α3: Kd = 40nM).
Die Produkte sind ausschließlich für Forschungszwecke bestimmt. Nicht zur Anwendung am Menschen. Wir verkaufen nicht an Patienten.
Cas No.: 465-21-4
10mM (in 1mL DMSO)In Stock
$54.00
1
5mgIn Stock
$49.00
1
10mgIn Stock
$78.00
1
25mgIn Stock
$133.00
1
50mgIn Stock
$200.00
1
100mgIn Stock
$280.00
1
| Pack Size | Price | Availability | Quantity | Action |
|---|---|---|---|---|
| 10mM (in 1mL DMSO) | $54.00 | In Stock | 1 | |
| 5mg | $49.00 | In Stock | 1 | |
| 10mg | $78.00 | In Stock | 1 | |
| 25mg | $133.00 | In Stock | 1 | |
| 50mg | $200.00 | In Stock | 1 | |
| 100mg | $280.00 | In Stock | 1 |
Tel: (909) 407-4943 / (909) 689-7124Email: sales@glpbio.com
Zitate (Citations)
1 publicationsPublikationen von Forschern, die dieses Produkt verwendenBeschreibung (Description)
Bufalin is a Na+/K+-ATPase inhibitor (α1: Kd = 42.5nM; α2: Kd = 45nM; α3: Kd = 40nM) [1]. Bufalin primarily inhibits the activity of Na⁺/K⁺-ATPase on cell membranes, leading to elevated intracellular calcium concentrations [2]. Bufalin induction of apoptosis and inhibition of tumor cell proliferation can also have multiple anti-tumor mechanisms, including triggering autophagy and inhibiting tumor angiogenesis [3]. Bufalin is used to treat various tumors, including liver cancer, lung cancer, breast cancer, and leukemia [4].
In NCI-H640 cells, after treatment with Bufalin (1μM, 2μM, 4μM; 24h), the activity of cells decreased significantly [5]. In Ishikawa, SK-OV-3 and OMC-3 ovarian cancer cells, Bufalin (0.1-10ng/mL; 48h) can inhibit the proliferation of endometrial and ovarian cancer cells [6]. In human RCC ACHN cells, Bufalin (0-80nM; 12-72h) suppresses the proliferation and metastasis of renal cell carcinoma by inhibiting the PI3K/Akt/mTOR signaling pathway [7].
In carrageenan-induced paw edema rat model, after Bufalin (0.15mg/kg, 0.3mg/kg, 0.6mg/kg; ip; single injection) treatmentthe, volume of paw edema in rats was significantly reduced [8]. In HCCLM3 cell metastatic orthotopic tumor mouse model, orthotopic transplanted tumor tissues undergo necrosis and apoptosis induced by Bufalin (1mg/kg, 1.5mg/kg; ip; 30d) treatment [9].
References:
[1]. Katz A, Lifshitz Y, Bab-Dinitz E, et al. Selectivity of digitalis glycosides for isoforms of human Na, K-ATPase[J]. Journal of Biological Chemistry, 2010, 285(25): 19582-19592.
[2]. Wu S H, Bau D T, Hsiao Y T, et al. Bufalin induces apoptosis in vitro and has Antitumor activity against human lung cancer xenografts in vivo[J]. Environmental Toxicology, 2017, 32(4): 1305-1317.
[3]. Yin P H, Liu X, Qiu Y Y, et al. Anti-tumor activity and apoptosis-regulation mechanisms of bufalin in various cancers: new hope for cancer patients[J]. Asian Pacific journal of cancer prevention, 2012, 13(11): 5339-5343.
[4]. Lan Y L, Lou J C, Jiang X W, et al. A research update on the anticancer effects of bufalin and its derivatives[J]. Oncology letters, 2019, 17(4): 3635-3640.
[5]. Wu S H, Wu T Y, Hsiao Y T, et al. Bufalin induces cell death in human lung cancer cells through disruption of DNA damage response pathways[J]. The American Journal of Chinese Medicine, 2014, 42(03): 729-742.
[6]. Takai N, Ueda T, Nishida M, et al. Bufalin induces growth inhibition, cell cycle arrest and apoptosis in human endometrial and ovarian cancer cells[J]. International journal of molecular medicine, 2008, 21(5): 637-643.
[7]. Xie J, Lin W, Huang L, et al. Bufalin suppresses the proliferation and metastasis of renal cell carcinoma by inhibiting the PI3K/Akt/mTOR signaling pathway[J]. Oncology letters, 2018, 16(3): 3867-3873.
[8]. Wen L, Huang Y, Xie X, et al. Anti‐inflammatory and antinociceptive activities of bufalin in rodents[J]. Mediators of inflammation, 2014, 2014(1): 171839.
[9]. Zhang Z J, Yang Y K, Wu W Z. Bufalin attenuates the stage and metastatic potential of hepatocellular carcinoma in nude mice[J]. Journal of translational medicine, 2014, 12(1): 57.
Protokoll (Protocol)
| Cell experiment [1]: | |
Cell lines | NCI-H640 cells |
Preparation Method | Approximately 2 × 105 cells/well of NCI-H640 cells in 12-well plates were incubated with Bufalin at final concentrations of 0 (vehicle, 0.5% DMSO), 1, 2 and 4μM for 24 hours. Cells from each treatment were stained with PI (5 g/ml) and analyzed by flow cytometry and cell viability was calculated. |
Reaction Conditions | 1μM, 2μM, 4μM; 24h |
Applications | After treatment with Bufalin, the activity of cells decreased significantly. |
| Animal experiment [2]: | |
Animal models | Carrageenan-induced paw edema rat model |
Preparation Method | The anti-inflammatory effect was based on the inhibition of carrageenan-induced hind paw edema. Bufalin (0.15, 0.3, and 0.6mg/kg, i.p.), indomethacin (10mg/kg, i.p.), and vehicle were administered intraperitoneally 30min prior to carrageenan injection. Each rat received a subplantar injection of carrageenan (0.1mL, 1% w/v in saline) in the right hind paw. A plethysmometer measured the volume of paw edema before and at various times (1, 2, 4, and 6h) after the carrageenan injection. The paw swelling ratio was calculated as a percentage increase from the paw volume measured prior to carrageenan injection. Rat paws were collected after the final assessment. Each hind paw was cut at the level of the calcaneus bone and used for Western blot analysis. |
Dosage form | 0.15mg/kg, 0.3mg/kg, 0.6mg/kg; ip; single injection |
Applications | After Bufalin treatment, the volume of paw edema in rats was significantly reduced. |
References: | |
Produktdokumente (Product Documents)
Purity:>99.50%Appearance:A solid
Chemische Eigenschaften (Chemical Properties)
CAS-Nr.
465-21-4
Synonyme
NSC 89595
Chemischer Name
5-[(3S,5R,8R,9S,10S,13R,14S,17R)-3,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]pyran-2-one
SMILES
CC12CCC(CC1CCC3C2CCC4(C3(CCC4C5=COC(=O)C=C5)O)C)O
Summenformel
C24H34O4
Molekulargewicht
386.52
Löslichkeit
≥ 38.7mg/mL in DMSO
Lagerung
Store at -20°C
Allgemeine Hinweise
Wählen Sie anhand der Löslichkeitsdaten des Produkts ein geeignetes Lösungsmittel. Aliquotieren Sie die Stammlösung nach der Herstellung, um wiederholte Gefrier-Auftau-Zyklen zu vermeiden.
Verwenden Sie Stammlösungen bei Lagerung bei -80°C innerhalb von 6 Monaten bzw. bei -20°C innerhalb von 1 Monat.
Zur Verbesserung der Löslichkeit das Röhrchen auf 37°C erwärmen und für eine angemessene Dauer beschallen.
Verwenden Sie Stammlösungen bei Lagerung bei -80°C innerhalb von 6 Monaten bzw. bei -20°C innerhalb von 1 Monat.
Zur Verbesserung der Löslichkeit das Röhrchen auf 37°C erwärmen und für eine angemessene Dauer beschallen.
Versandbedingungen
Evaluierungsmuster werden mit Kühlakkus versandt. Andere verfügbare Größen werden bei Raumtemperatur oder auf Anfrage mit Kühlakkus versandt.
Rechner (Calculators)Molarität / Verdünnung / Molekulargewicht / Einheitenumrechnung / In-vivo-Formulierung / Löslichkeit
g/mol
Reviews
Review for Bufalin
Rating: 5
- 5 Star100%
- 4 Star0%
- 3 Star0%
- 2 Star0%
- 1 Star0%